Technical analysis of FibroBiologics, Inc. Common Stock (FBLG): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair.
Price Performance
| 1 month | +21.93% |
| 3 months | +80.47% |
| Year-to-date | -69.11% |
| 1 year | -86.77% |
52-Week Range
| 52-week High | $12.40 |
| 52-week Low | $0.62 |
| Avg Volume (90d) | 226K |
Technical Indicators
| SMA 50 | $1.15 |
| SMA 200 | $3.10 |
| 30-day Volatility (annualised) | 126.4% |
| Price vs SMA 50 | +21.0% |
| Price vs SMA 200 | -55.2% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $7.87 | |
| 2025-11 | $5.48 | -30.4% |
| 2025-12 | $4.50 | -17.9% |
| 2026-01 | $6.64 | +47.6% |
| 2026-02 | $6.57 | -1.1% |
| 2026-03 | $1.32 | -79.9% |
| 2026-04 | $1.32 | +0.0% |
| 2026-05 | $1.16 | -12.1% |
| 2026-06 | $0.95 | -18.3% |
| 2026-07 | $0.70 | -26.1% |
| 2026-08 | $1.72 | +145.7% |
| 2026-09 | $1.39 | -19.2% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-15 | | |
| 2026-09-15 | $-0.02 | |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
Price
| Price | $1.43 |
| Market Cap | $3M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.16 |
| EV / EBITDA | -0.10 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.32 |
| Current Ratio | 2.64 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -11.28 |